Table 1.
Correlation between human panCAF and myCAF signatures with clinicopathological parameters in a human cohort of 119 ICC patients
| panCAF low | panCAF high | Total | p value | myCAF low | myCAF high | Total | p value | |
|---|---|---|---|---|---|---|---|---|
| n (%) | 59 | 60 | 119 | 59 | 60 | 119 | ||
| Molecular class | ||||||||
| Proliferation class | 18 (31) | 54 (90) | 72 (60) | 0.0001 | 20 (34) | 52 (87) | 72 (60) | 0.0001 |
| Inflammation class | 41 (69 | 6 (10) | 47 (40) | 39 (66) | 8 (13) | 47 (40) | ||
| Demographics | ||||||||
| Sex, n (%) | ||||||||
| Male | 28 (47) | 37 (62) | 65 (55) | 0.142 | 29 (49) | 36 (60) | 65 (55) | 0.272 |
| Age, years | ||||||||
| Median (IQR) | 62 (54–70) | 64 (55–70) | 64 (54–70) | 0.91 | 62 (53–71) | 64 (56–69) | 64 (54–70) | 0.901 |
| Race, n (%) | ||||||||
| Caucasian | 56 (96) | 52 (86) | 108 (92) | 0.178 | 56 (97) | 52 (87) | 108 (92) | 0.018 |
| African American | 1 (2) | 1 (2) | 2 (2) | 2 (3) | 0 (0) | 2 (2) | ||
| Asian | 0 (0) | 3 (5) | 3 (3) | 0 (0) | 3 (5) | 3 (2) | ||
| Other | 1 (2) | 4 (7) | 5 (3) | 0 (0) | 5 (8) | 5 (4) | ||
| Viral hepatitis, n (%) | ||||||||
| Hepatitis C | 11 of 57 (19) | 8 of 60 (13) | 19 (16) | 0.267 | 12 (21) | 7 (12) | 19 (16) | 0.219 |
| Hepatitis B | 5 (9) | 6 (10) | 11 (9) | 1 | 7 (12) | 4 (7) | 11 (9) | 0.362 |
| Cirrhosis, n (%) | 8 (15) | 12 (23) | 20 (19) | 0.331 | 8 (15) | 12 (20) | 20 (19) | 0.458 |
| Total bilirubin, n (%) | ||||||||
| >1 mg/dL | 14 (25) | 10 (18) | 24 (21) | 0.492 | 13 (24) | 11 (19) | 24 (21) | 0.648 |
| Serum ALT, n (%) | ||||||||
| >40 IU/L | 12 (21) | 19 (33) | 31 (27) | 0.206 | 12 (21) | 19 (33) | 31 (27) | 0.209 |
| Tumor features (pathologic) | ||||||||
| Tumor diameter, cm | ||||||||
| Median (IQR) | 6 (4–9) | 7 (5–9) | 6 (4–9) | 0.096 | 6 (4–8) | 7 (5–11) | 6 (4–9) | 0.095 |
| Tumor number, n (%) | ||||||||
| Single | 47 (80) | 52 (87) | 99 (83) | 0.337 | 48 (81) | 51 (85) | 99 (83) | 0.632 |
| Multiple | 12 (20) | 8 (13) | 20 (17) | 11 (19) | 9 (15) | 20 (17) | ||
| Cell differentiation, n (%) | ||||||||
| Well | 14 (30) | 4 (8) | 18 (19) | 0.009 | 11 (24) | 7 (14) | 18 (19) | 0.298 |
| Moderate-poor | 33 (70) | 44 (92) | 77 (81) | 35 (76) | 42 (86) | 77 (81) | ||
| Stagea, n (%) | ||||||||
| I + II | 36 (62) | 34 (57) | 58 (49) | 0.579 | 38 (64) | 32 (54) | 70 (59) | 0.349 |
| III + IV | 22 (38) | 26 (43) | 21 (36) | 27 (46) | 48 (41) | |||
| Macrovascular invasion, n (%) | 4 (7) | 12 (20) | 16 (13) | 0.058 | 4 (3) | 12 (20) | 24 (20) | 0.058 |
| Invasion of peritoneum, n (%) | 0 (0) | 4 (7) | 4 (3) | 0.119 | 0 (0) | 4 (7) | 4 (3) | 0.119 |
| Infiltration of resection margins, n (%) | 22 (37) | 32 (53) | 54 (45) | 0.1 | 21 (36) | 33 (55) | 54 (45) | 0.09 |
| Invasion of bile duct, n (%) | 1 (2) | 5 (8) | 6 (5) | 0.207 | 1 (2) | 5 (83) | 6 (5) | 0.207 |
| Intraneural invasion, n (%) | 4 (7) | 16 (27) | 20 (17) | 0.006 | 4 (7) | 16 (27) | 20 (17) | 0.006 |
| Satellites, n (%) | 14 (24) | 15 (25) | 29 (24) | 0.837 | 15 (25) | 17 (28) | 32 (27) | 0.837 |
Variables included here have less than 10% of missing values except for cell differentiation (n = 24, 20% missing). IQR, interquartile range. p values in boldface are significant.
a
Data according to the AJCC TNM stage, 7th edition.